Table 2.
Cytotoxicity and pharmacodynamics study of ORI nanosuspension.
| Research Objects | Biological Activity or Mechanism | Ref. |
|---|---|---|
| New Zealand white rabbits, Kunming strain mice | Particle size affects pharmacokinetics and tissue distribution | [68] |
| K562 cell, S-180 tumor-burdened mice | Significantly more toxic to K562 cells than free ORI (p < 0.01) | [69] |
| PC-3 cell | Inducing early apoptosis and enhancing growth suppression | [70] |
| SMMC-7721 cell, H22 tumor-bear mice | Arresting cells in the G2/M phase, tumor volume response ORI-N has a higher anti-tumor effect | [71] |
| MCF-7 cell | Reducing the expression of Bcl-2 and increasing Bax | [72] |
| PANC-1 cell | Suppressing the expression of B1 and p-cdc2 (T161) on G2/M cell phase | [73] |
| SD-rats | Improving dissolution and permeability by interaction with absorptive epithelia and anti-drug efflux. | [74] |
SD = Sprague Dawley.